CG Oncology targets near $1 bln valuation in US IPO | Reuters

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

CouponFollow Extension

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

23 hours ago

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$1
OFF

UPDATE 1-CG Oncology Targets Near $1 Bln Valuation In US IPO

23 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. CG Oncology is one of a handful of companies …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

23 hours ago

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

23 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO - Yahoo …

23 hours ago

Jan 18, 2024 · The company is developing a therapy for patients with bladder cancer. Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. …

yahoo.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

23 hours ago

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

usnews.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

23 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

23 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO

23 hours ago

Jan 18, 2024 · CG Oncology targets near $1 billion valuation in US IPO. ... Savio D'Souza Shounak Dasgupta. REUTERS • January 18, 2024 (Reuters) -Cancer drug developer CG …

westlaw.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

23 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.The company is developing a therapy for …

tradingview.com

6%
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

23 hours ago

5 days ago · CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. …

stockanalysis.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

23 hours ago

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

23 hours ago

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$1
OFF

CG Oncology's Lead Bladder Cancer Drug Offers Buyout …

23 hours ago

Jan 25, 2024 · A more specific example, RayzeBio, Inc. , which has an oncology drug in Phase III trials, which was valued at a similar amount of approximately $1.1 billion dollars post-IPO.

seekingalpha.com

FAQs about CG Oncology targets near $1 bln valuation in US IPO | Reuters Coupon?

How much is CG oncology worth?

(Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new listings pick up after a two-year dry spell. ...

Will CG oncology raise $306 million?

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

How many shares will CG oncology offer?

CG Oncology did not say how many shares it planned to offer or give an estimated price range. The company plans to use proceeds primarily for supporting operations. The company has applied to list its shares on the Nasdaq Global Market under the ticker CGON. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...